Post-ECC 2015 Review and Analysis: Current Science of Immunotherapies for the Management of Patients with Non-small Cell Lung Cancer

http://academiccme.com/wp-content/uploads/2016/01/iStock_000017383155_Small-wpcf_400x400.jpg

Course Information

Therapautic Area: Oncology
Format(s): Webcast, Downloadable Transcript , Post Conference Review and Analysis
Credit(s): 1.00 AMA PRA Category 1 Credit(s)™
Activity Dates: January 22, 2016 - March 21, 2017

 

Program Overview

This CME Program will review and analyze data presented at ECC 2015 regarding advancements in the treatment and management of patients with Non-small cell lung cancer. Expert faculty will review the pathogenesis and clinical development of the disease for both squamous and non-squamous patients. The most effective ways to implement recent clinical advancements into everyday practice and improve patient outcomes will be discussed. This program is designed to acquaint physicians with existing and introductory drugs to improve the percentage of physicians who feel very confident in their ability to prescribe treatment in this therapeutic area. With the information provided in this activity, learners will be equipped with the most up-to-date clinical data they need to administer optimal care to their non-small cell lung cancer patients.

Target Audience

Oncologists and other healthcare professionals responsible for the diagnosis, treatment or management of patients with NSCLC.

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Review the current science and clinical trial data for immunotherapies, including PD-1 inhibitors, for patients with non-small cell lung cancer.
  2. Analyze the relevant data from ECC 2015 to apply to the most up-to-date immunotherapies for the treatment of non-small cell lung cancer.

Faculty

Mark G. Kris, MD
Member and Attending Physician
William and Joy Ruane Professor of Thoracic Oncology
Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College
New York, NY

Corey Langer, MD
Professor of Medicine
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA

Catherine Pietanza, MD
Assistant Attending Physician
Thoracic Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures of Conflicts of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Relationship Identified With:
Mark G. Kris, MD Consultant/Advisor: AstraZeneca; Genentech, Inc.; ARIAD Pharmaceuticals, Inc.
Corey Langer, MD Consultant/Advisor: AstraZeneca; Bristol-Myers Squibb Company; Genentech, Inc.
Grant/Research Support: Merck & Co., Inc.
M. Catherine Pietanza, MD Consultant/Advisor: AbbVie, Inc; Bristol-Myers Squibb Company; Celgene Corporation
Grant/Research Support: Bristol-Myers Squibb Company; Novartis AG; OncoMed Pharmaceuticals, Inc; Stemcentrx, Inc.

Timothy Hayes, MD, PhD; Kristen Scollon; Emma Gilmartin and Nicole Brestowski hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Bristol-Myers Squibb Company.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Bristol-Myers Squibb Company do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact admin@academiccme.com.
BUTTON